HDAC9 and glioblastoma: Furthermore, combining the HDAC inhibitor vorinostat with a multitargeted tyrosine kinase inhibitor (TKI), vandetanib, can prevent EGFR, vascular EGFR (VEGFR), and Ret-dependent signaling, thereby inhibiting growth, preventing Akt signaling, and stimulating apoptosis in glioblastoma cells [160].